Valiant Laboratories IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: Oct 06, 2023Let’s have a detailed review of the company and analytics of the Valiant Laboratories IPO release date, IPO offer price, subscription, Valiant Laboratories Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.
| Face Value | Rs 10 |
| Price Band | Rs 133 to Rs 140 |
| Listing At | BSE, NSE |
| Min. Order Quantity | 105 Shares |
| Listing Date | October 9, 2023 |
| Offer for Sale | Rs Million |
| Fresh Issue | Rs 1524.6 Million |
| IPO Size | Rs 1524.6 Million |
| Tick Size | 1 |
Valiant Laboratories IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.
| Live Performance – Valiant Laboratories Share Price |
Valiant Laboratories IPO – Summary
They are an Active Pharmaceutical Ingredient (“API”)/ Bulk Drug manufacturing company having a focus on manufacturing Paracetamol.
Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxy acetanilide -C8H9NO2), is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions.
The Promoter of this company is SHANTILAL SHIVJI VORA AND DHANVALLABH VENTURES LLP. The lead manager of the issue is UNISTONE CAPITAL PRIVATE LIMITED, and the Registrar of this issue is LINK INTIME INDIA PRIVATE LIMITED.
Check out Related IPO Links:
| Valiant Laboratories IPO GMP |
| Valiant Laboratories IPO Allotment |
| LIVE Subscription – Valiant Laboratories IPO |
Valiant Laboratories IPO Date
The opening and closing dates of Valiant Laboratories IPO are September 27, 2023 and October 3, 2023 respectively.
Valiant Laboratories IPO Subscription
| Day / Date | QIB | NII | RII | Total Subscription |
| 1st Day – 27th Sep | 0.00x | 0.10x | 0.62x | 0.33x |
| 2nd Day – 28th Sep | 0.05x | 0.29x | 1.29x | 0.72x |
| 3rd Day – 29th Sep | 1.04x | 1.52x | 3.14x | 2.19x |
| 4th Day – 3rd Oct | 20.83x | 73.64x | 16.06x | 29.76x |
| Shares Offered or Net Issue | 2,178,030 | 1,633,500 | 3,811,500 | 10,890,000 |
The shares subscribed by the public will be updated here.
Valiant Laboratories IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Allotment of Equity Shares are pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.
Valiant Laboratories Limited IPO Listing Date
Find the dates below on basis of allotment, refund, listing, and more:
| Basis of Allotment Finalization | October 5, 2023 |
| Refunds Initiation | October 6, 2023 |
| Credit of Shares to Demat Account | October 7, 2023 |
| Share Listing Date | October 9, 2023 |
Valiant Laboratories IPO Price Band
The face value of each share is Rs.10, but the price band of the IPO is Rs 133 to Rs 140
Valiant Laboratories IPO Equity Size
This Initial Public Issue of 10,890,000 Equity Shares of Rs.10 each for cash at a price of Rs 133 to Rs 140 per equity share aggregating to Rs.1524.6 Million.
Valiant Laboratories IPO Share Offering
Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of 10,890,000 Equity Shares of Rs.10/ each.
Issue Size: 10,890,000 Equity Shares of Rs.10 each, aggregating to Rs.1524.6 Million
Open Free Demat Account Now!
Valiant Laboratories IPO – Live Performance
The listing date of this IPO is October 9, 2023. You can check the live performance of the IPO here, only after it is listed on exchanges.
| Live IPO Performance – Valiant Laboratories Share Price |
Valiant Laboratories IPO Grey Market Premium
The Valiant Laboratories Limited IPO Grey Market Premium price is Rs 25, the Kostak rate is Rs NA and the Subject to Sauda is Rs NA.
Valiant Laboratories IPO – Company Overview
Paracetamol was initially approved by the U.S. Food and Drug Administration (“US FDA”) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms.
So, Paracetamol is often found combined with other drugs in many over-the-counter (“OTC”) allergy medications, cold medications, sleep medications, pain relievers, and other products.
The pharmaceutical API industry in India is ranked third-largest globally in terms of volume, behind China and Italy –About 35 per cent of API and intermediaries produced in India are exported and the remaining API and intermediaries are sold in the domestic market, including captive consumption by several large formulation players.
India is the largest provider of generic drugs, globally contributing to ~20% of global supply by volume of generic drugs.
Valiant Laboratories IPO – Financial Statements
A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:
Financial Summary:
| Amount (in INR & Million) | |||
| 31-Mar-23 | Mar-22 | 31-Mar-21 | |
| Total Assets | 2127.58 | 1818.12 | 1063.14 |
| *Total Revenue | 3387.72 |
2934.72
|
1837.81
|
| Total Expense |
3006.36
|
2517.68
|
1367.59
|
| Profit After Tax |
289.98
|
274.96
|
305.93
|
Earnings per Equity Share (in Million)
| 31-Mar-23 | Mar-22 | 31-Mar-21 | |
| Basic & Diluted |
8.91
|
9.52
|
10.83
|
Further, their PAT for the period ended on March 31, 2023, March 31, 2022, and March 31, 2021, were Rs. 289.98 Million, Rs. 274.96 Million and Rs. 305.93 Million respectively.
Valiant Laboratories IPO – Promoters
The Promoter of this company is:
- SHANTILAL SHIVJI VORA
- DHANVALLABH VENTURES LLP
List of Related Parties (Key Managerial Personnel)
- Velji Karamshi Gogri, Chairman and Independent Director
- Santosh Shantilal Vora, Managing Director
- Shantilal Shivji Vora, Non-Executive & Non-Independent Director
- Paresh Shashikant Shah, Executive Director
- Sonal Amit Vira, Independent Director
Valiant Laboratories IPO – Promoters Holding
- Pre-Issue Share Holding – 100.00%
- Post-Issue Share Holding – 74.94%
Valiant Laboratories IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Equity Shares Offered | Up to 10,890,000 Equity Shares aggregating up to Rs.1524.6 Million |
| of which: | |
| Issue Reserved for the Market Makers | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Net Issue to the Public | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Of which: | |
| Retail Investors Portion | Not less than [●] Equity Shares |
| Other than Retail Individual Investors | Not more than [●] Equity Shares |
| Equity Shares outstanding prior to the Issue | 32,560,000 Equity Shares |
| Equity Shares outstanding after the Issue | X Equity Shares |
Valiant Laboratories IPO Issue Object
Their Company proposes to utilize the Net Proceeds towards funding the following objects:
- Investment in their wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (“VASPL”) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for speciality chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (“Proposed Facility”);
- Investment in VASPL for funding its working capital requirements; and
- General corporate purposes
Valiant Laboratories IPO – Business Strategy
- Diversification into new chemistries and industry
- Increase in market share
- Improve operational efficiencies through backward integration of the Proposed Facility
- Increase their penetration into international markets including regulated markets
Valiant Laboratories IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Experienced promoters and a strong management team.
- Strong Focus on Sustainability in Operations.
- Strategically located manufacturing facility.
- Quality-Focused Compliant Manufacturing and R&D Infrastructure.
- Reducing dependence on import of raw materials.
The relevant quantitative factors are:
| Basic & Diluted EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-23 |
8.91
|
28.86 | 30.86 |
| 31-Mar-22 |
9.52
|
38.48 | – |
| Mar-21 |
10.83
|
34.54 | – |
Valiant Laboratories IPO: Competitive Peers
| Face Value (Rs.) | P/E | EPS (Rs.) | Return on Net Worth (%) | Revenue from operations (Rs. in Millions) | |
| Valiant Laboratories Limited | 10 | [●] |
8.91
|
28.90
|
3,339.10
|
| Listed Peers | |||||
| Granules India Ltd | 1 |
13.19
|
21.05
|
18.22
|
45,119.17
|
| Jagsonpal Pharmaceuticals Limited | 1 |
36.03
|
10.2
|
16.82 |
2,367.14
|
Valiant Laboratories IPO Lead Managers
| Lead Managers |
| UNISTONE CAPITAL PRIVATE LIMITED A/ 305, Dynasty Business Park, Andheri-Kurla Road, Andheri East, Mumbai –400 059, India. Telephone:+91 9820057533 Email: mb@unistonecapital.com Investor grievance email: compliance@unistonecapital.com Contact Person:Brijesh Parekh Website: www.unistonecapital.com SEBI registration number: INM000012449 CIN: U65999MH2019PTC330850 |
Valiant Laboratories IPO Registrar to offer
| Registrar to the Offer |
| LINK INTIME INDIA PRIVATE LIMITED C-101, 247 Park, 1st Floor L.B.S. Marg, Vikhroli West Mumbai 400 083, Maharashtra, India Telephone:+91 8108114949 Facsimile:+91 2249186060Email: valiantlaboratories.ipo@linkintime.co.in Investor grievance email:valiantlaboratories.ipo@linkintime.co.in Contact Person: Shanti Gopalkrishnan Website: www.linkintime.co.in SEBI Registration Number: INR000004058 CIN: U67190MH1999PTC118368 |
Valiant Laboratories IPO – Other Details
- Statutory Auditor – Raman S Shah & Co
- Legal Counsel to the Company – M/s. Alliance Law
- Bankers to the Company – Kotak Mahindra Bank Limited
Valiant Laboratories IPO Review by Stock Brokers
| Top Stock Brokers Review | Company Reputation | Competitive Edge | Financial Statement | Popularity Index | Promoters Reputation |
| Angel Broking | 7.5/10 | 7.4/10 | 8.5/10 | 8.1/10 | 7.1/10 |
| Sharekhan | 7.2/10 | 7.1/10 | 8.6/10 | 8.1/10 | 7.2/10 |
| Kotak Securities | 7.3/10 | 7.5/10 | 8.4/10 | 8.1/10 | 7.3/10 |
| ICICI Direct | 7.3/10 | 7.3/10 | 8.7/10 | 8.1/10 | 7.1/10 |
| IIFL | 7.5/10 | 7.2/10 | 8.8/10 | 8.0/10 | 7.1/10 |
| Edelweiss | 7.5/10 | 7.4/10 | 8.4/10 | 8.3/10 | 7.2/10 |
| Zerodha | 7.4/10 | 7.1/10 | 8.5/10 | 8.1/10 | 7.0/10 |
| 5Paisa | 7.1/10 | 7.1/10 | 8.4/10 | 8.1/10 | 7.1/10 |
| Karvy | 7.4/10 | 7.3/10 | 8.2/10 | 8.1/10 | 7.1/10 |
| Motilal Oswal | 7.1/10 | 7.1/10 | 8.6/10 | 8.3/10 | 7.2/10 |
Subscribe to Valiant Laboratories IPO
Valiant Laboratories Limited IPO News
News 1 – IPO DRHP Download
News 2 – IPO RHP Prospectus Download
Valiant Laboratories IPO Review FAQs
Check out various FAQs related to Valiant Laboratories IPO:
What is the Issue Size of Valiant Laboratories IPO?
The Company is making an initial public offer of 10,890,000 equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Valiant Laboratories IPO?
The price band for this particular IPO ranges between Rs 133 to Rs 140. As far as the face value of the share is concerned, it is Rs. 10 per share.
What is the Valiant Laboratories IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on September 27, 2023, while the closing date is set at October 3, 2023.
What is the Valiant Laboratories IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on October 5, 2023, refund initiation is on October 6, 2023, credit of shares is on October 7, 2023, and share listing date is on October 9, 2023.
What is the Valiant Laboratories IPO Listing Date?
Shares of this company shall be listed in the exchanges on October 9, 2023. The date, when the listing would be done, is stagnant on October 9, 2023.
Who is the Registrar of Valiant Laboratories IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. LINK INTIME INDIA PRIVATE LIMITED. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Valiant Laboratories IPO?
Here are the promoters of this IPO – SHANTILAL SHIVJI VORA AND DHANVALLABH VENTURES LLP. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Valiant Laboratories IPO?
They have obtained the GMP of this IPO and it is Rs 25. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.
Is Valiant Laboratories IPO Good for Investment?
They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Valiant Laboratories Company?
They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2023 in Million is 289.98, 2022 is 274.96, and 2021 is 305.93.
Calculate your return on investment!
Asset Class
ROI (Rs.)
Profit (Rs.)
Profit (%)
IPO
Equity
Savings
Real Estate
Gold
Bonds
Fixed Deposit
Mutual Fund
Featured Topics